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Abstract
Neuronal pentraxin 1 (NPTX1) has been implicated in Alzheimer’s disease, being present in and around dystrophic neurons
in plaques, affecting glutamatergic transmission postsynaptically and mediating effects of amyloidβ. Here, we conﬁrm the
presence of NPTX1 around plaques in postmortem Alzheimer’s disease brain and report that acutely applied human NPTX1
increases paired-pulse ratio at mouse CA3-CA1 hippocampal synapses, indicating a decrease in glutamate release. In
contrast, chronic exposure to NPTX1, NPTX2, or NPTX receptor decreases paired-pulse ratio, mimicking some of the earliest
changes in mice expressing familial Alzheimer’s disease genes. The peripheral pentraxin, serum amyloid P component
(SAP), causes similar synaptic effects to NPTX1. The presence of SAP on amyloid plaques in Alzheimer’s disease conﬁrms
that it can enter the brain. We show that SAP and neuronal pentraxins can interact and that SAP can enter the brain if the
blood–brain barrier is compromised, suggesting that peripheral pentraxins could affect central synaptic transmission via
this interaction, especially in the event of blood–brain barrier breakdown.
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Introduction
Several members of the pentraxin family, the neuronal pen-
traxins 1 (NPTX1), 2 (NPTX2, also known as neuronal activity
regulated pentraxin, NARP), and the neuronal pentraxin recep-
tor (NPTXR) are expressed in neurons of the central nervous
system (Schlimgen et al. 1995; Tsui et al. 1996), where, under
normal physiological conditions, they modulate synaptic trans-
mission. NPTX1 is constitutively released from excitatory term-
inals, while release of NPTX2 is activity-dependent (Tsui et al.
1996; Kirkpatrick et al. 2000). In contrast, NPTXR can be
membrane-bound, with 1 transmembrane spanning domain,
although it has also been shown to have multiple intracellular
isoforms (Chen and Bixby 2005). The membrane-bound form can
be cleaved enzymatically to release a diffusible form (Kirkpatrick
et al. 2000). These 3 pentraxins have effects on postsynaptic glu-
tamate receptors, with NPTX2 alone or in a complex with NPTX1
and NPTXR enhancing α-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid (AMPA) receptor clustering in excitatory synap-
ses, including those onto parvalbumin-positive interneurons
(O’Brien et al. 1999; Xu et al. 2003; Chang et al. 2010; Pelkey
et al. 2015). It should be noted that, while the nomenclature
NPTX “receptor” comes from the fact that NPTXR was initially
hypothesized to be a receptor for the other pentraxins, there
is little evidence that the primary mode of action of the other
NPTXs is via NPTXR acting as a receptor in the classical sense.
The different NPTXs, together or separately, have been impli-
cated in synaptogenesis (Sia et al. 2007; Figueiro-Silva et al. 2015),
synaptic plasticity (Xu et al. 2003), synaptic homeostasis (Pribiag
and Stellwagen 2014), and metabotropic glutamate receptor-
mediated long-term depression (Cho et al. 2008). Moreover,
NPTX1 has been implicated in Alzheimer’s disease, where it is
present in dystrophic neurites around plaques in postmortem
brain (Abad et al. 2006), possibly contributing to apoptosis via
effects on mitochondria (Clayton et al. 2012). Furthermore,
amyloidβ-induced increase in NPTX1 expression has also been
implicated in neuronal toxicity (Abad et al. 2006).
In contrast to the NPTXs, the short pentraxin serum amyloid
P component (SAP, encoded by the gene APCS), is synthesized
in the liver (Pepys and Hirschﬁeld 2003). In humans, SAP
remains at a fairly stable circulating plasma concentration
(~10–100 µg/mL [~0.4–4 µM, based on 25 kDa monomer]; Pepys
et al. 1978), while in mice, SAP acts as an acute-phase response
protein (Pepys and Hirschﬁeld 2003). Penetration of SAP
through the blood–brain barrier is normally poor, resulting in
low nanomolar concentrations in cerebrospinal ﬂuid, in both
healthy subjects and people with Alzheimer’s disease (Kalaria
et al. 1991; Hawkins et al. 1994; Kimura et al. 1999). However,
this substantial concentration gradient makes SAP a likely can-
didate for increased penetration to the brain under conditions
of blood–brain barrier breakdown, as occurs in many cases of
Alzheimer’s disease (Blennow et al. 1990; Montagne et al. 2015).
Indeed, the presence of SAP on plaques and neuroﬁbrillary tan-
gles in Alzheimer’s disease indicates that some penetration
indeed occurs (Kalaria et al. 1991). When exogenously applied
to central neurons in culture from rat brains, at concentrations
found in serum, SAP binds to and enters neurons in vivo and
in vitro, resulting in apoptosis (Urbanyi et al. 1994, 2007; Duong
et al. 1998). Although these high concentrations are normally
unlikely to occur in the brain, with breakdown of the blood–
brain barrier the concentration gradient could result in sub-
stantial increases in SAP concentrations centrally.
Considering the structural similarity of SAP to the NPTXs,
the question arises whether inﬁltrating SAP could mimic or
otherwise interact with these central pentraxins in modulating
synaptic transmission in the central nervous system. If SAP is
active at central synapses, this could have substantial cognitive
consequences, particularly under conditions where a weakened
blood–brain barrier results from peripheral inﬂammation, as
commonly occurs in such conditions as urinary tract infections
in old age (Manepalli et al. 1990).
The current study focuses on NPTX1, as it has been clearly
implicated in Alzheimer’s disease and as its expression in glu-
tamatergic synapses in the central nervous system has been
shown to be enhanced by amyloidβ (Abad et al. 2006). However,
as the 3 NPTXs can function as a complex in synaptic modula-
tion, we have also compared the effects of NPTX2 and NPTXR.
Moreover, in light of its penetration into the brain in
Alzheimer’s disease and likely other conditions of blood–brain
barrier breakdown, we conﬁrm that SAP can enter the brain
under these conditions and report for the ﬁrst time that this
peripheral pentraxin has potent effects on central excitatory
synaptic transmission and interacts with the NPTXs.
Materials and Methods
See Supplementary Materials and Methods for further details.
Puriﬁed Native and Recombinant Pentraxin Proteins
Recombinant human NPTXs were obtained from R&D Systems
and human native puriﬁed SAP from Abcam. Pentraxins were
resuspended according to the molecular weight of the mono-
meric structure and serial dilutions made to obtain working
concentrations in culture medium. As the human puriﬁed SAP
contained sodium azide and ethylenediaminetetraacetic acid,
to avoid any off-target effects, the SAP was desalted by buffer
exchange as described by Pilling and Gomer (2012).
Animals
Mice transgenic for the human APCS (SAP) gene, including 5′
and 3′ ﬂanking sequences (Iwanaga et al. 1989) were back-
crossed with C57BL/6 J to establish a colony at UCL (TgSAP).
Age-matched wild type littermates and C57BL/6 J mice were
used as controls. C57BL/6 J mice were also used for generating
organotypic slices. All experiments were performed in agree-
ment with the Animals (Scientiﬁc Procedures) Act, 1986 and
with local ethical approval.
Organotypic Hippocampal Slices
Organotypic slices were prepared under sterile conditions from
5- to 7-day-old C57BL/6 J mouse pups using standard methods
(Stoppini et al. 1991; De Simoni et al. 2003; De Simoni and Yu
2006). For slices treated with human pentraxins, SAP or NPTX1,
2 or receptor was dissolved in the culture medium and applied
for 7 days starting at 11–17 days in vitro. Both control and trea-
ted slices were used for experimentation at 18–24 days in vitro.
Acute Hippocampal Slices
Preparations of acute hippocampal slices were made using
standard methods modiﬁed from Edwards et al. (1989) adapted
for mouse (Cummings et al. 2015). Brieﬂy, mice were killed by
decapitation and the brain rapidly removed to ice-cold dissec-
tion artiﬁcial CSF containing 3mM Mg++ and 0.5mM Ca++.
Slices transverse to the hippocampus were cut and gradually
moved to a more physiological (1mM Mg++ and 2mM Ca++)
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solution. Slices were allowed to recover at room temperature
before experimentation.
Patch-Clamp Recordings
Voltage-clamp (membrane holding potential −70mV) record-
ings were made in the whole-cell conﬁguration at room tem-
perature using a CsCl-based internal solution as previously
described (Cummings et al. 2015). Pairs of stimuli were applied
once every 10 s via a patch electrode ﬁlled with artiﬁcial CSF,
placed extracellularly in the Schaffer-collateral projections.
Field Potential Recordings
Slices were transferred to a heated (30 ± 1°C) submerged cham-
ber, superfused with artiﬁcial CSF and allowed to recover for
1 h in the recording chamber. Glass stimulating and recording
electrodes (ﬁlled with artiﬁcial CSF) were positioned in stratum
radiatum of CA1 to record a dendritic ﬁeld excitatory postsy-
naptic potential (fEPSP). Long-term potentiation conditioning
consisted of 5 trains of tetani, each consisting of 100 pulses at
100Hz, 1.5 s intertrain interval.
Quantitative Real-Time PCR
Quantitative real-time PCR primers were designed to span exon
boundaries to distinguish between the PCR ampliﬁcation from
cDNA versus contaminating genomic DNA.
The speciﬁcity of the Apcs (SAP gene) primers was assessed
using cDNA from wild type mouse liver. Forward and reverse
primers were incubated with cDNA samples, each primer and
KAPA2G PCR ReadyMix, resolved using a 3% agarose gel with
ethidium bromide and visualized using Bio-Rad Chemi-Doc MP
imaging system. A single band of the predicted product size
(155 bp) was observed for the Apcs primer pair, with no band
observed in the control lanes (cDNA synthesis reaction lacking
reverse transcriptase), or in the cDNA from the cortex. To inde-
pendently assess the speciﬁcity of these primers, a melt curve
analysis was performed following PCR of liver cDNA on a CFX96
system and by incubating PCR products containing SYBR green
PCR mix. A single peak corresponding to one product size was
observed for the Apcs primers. To assess the efﬁciency of the
primers, a dilution series of the liver cDNA was tested by PCR
using the SYBR green PCR mix in triplicate and the data plotted
for DNA dilution versus Cq with a line of best ﬁt. The efﬁciency
value for the primer pair was 0.98 with an r2 value of 0.99, dem-
onstrating the primer pair efﬁciency was close to 100% with
low technical variation.
Generation of Pentraxin Constructs
Total RNA was extracted from hippocampal tissue of mice
using the miRNeasy protocol (Qiagen). cDNA synthesis was per-
formed using high-capacity cDNA reverse transcription. The
entire cDNA sequence for Apcs, Nptx1, Nptx2, and Nptxr was
ampliﬁed by PCR using the primers listed in Supplementary
Table 1 and then subcloned into a plasmid with enhanced
green ﬂuorescent protein (GFP)-N1 expression using the EcoRI
and BamHI restriction sites upstream of GFP to create a
pentraxin-GFP fusion.
Pentraxin Antibodies and Western Immunoblotting
Antibody speciﬁcity was tested by Western immunoblotting
using lysates from human embryonic kidney (HEK293T) cells
overexpressing each of these pentraxin family members individu-
ally (Supplementary Fig. 2A,B). The antibodies in Supplementary
Table 2 were demonstrated to be speciﬁc for the pentraxin they
were raised against.
Western blotting was performed using sodium dodecyl sulfate
polyacrylamide gel electrophoresis and transfer to nitrocellulose
membranes. The membranes were blocked with 5% nonfat milk
in Tris-buffered saline with 0.1% Triton-X and then incubated
with the appropriate pentraxin antibody (Supplementary Table 2),
followed by incubation with horseradish peroxidase-conjugated
secondary antibody. Protein bands were visualized using
enhanced chemiluminescence.
Coimmunoprecipitation
HEK293T cell lines were transfected with 20 μg plasmid contain-
ing GFP-Nptx1, -Nptx2, -Nptxr, -Apcs (SAP), empty plasmid, or a
combination of two. After a 48 h incubation, cells were washed
and scraped into immunoprecipitation (IP) buffer. The coimmu-
noprecipitation procedure was adapted from that of O’Brien
et al. (1999). Brieﬂy, Protein-G and L agarose beads were washed
in IP buffer, then coupled to the appropriate antibody
(Supplementary Table 2). Following incubation, the beads were
washed and the collected cells sonicated then centrifuged. The
supernatant was added to the coupled beads and incubated
overnight then centrifuged and supernatant collected and fro-
zen. The coupled beads were then washed and protein samples
collected by boiling in 3× Laemmli buffer and subsequently
diluted to 1× Laemmli for loading.
Immunohistochemistry
Tissue sections (7 μm thick) were cut from the hippocampi of 4
sporadic Alzheimer’s disease cases (Table 1). Ethical approval
for the study was obtained from the National Hospital for
Neurology and Neurosurgery Local Research Ethics Committee.
Immunohistochemistry against NPTX1 and SAP (Supplementary
Table 2) required antigen retrieval followed by standard immu-
nohistological procedures (Lashley et al. 2011). Color was devel-
oped with diaminobenzidine/H2O2 and counterstained with
hematoxylin.
For mouse brains, immunoperoxidase histochemistry was
performed on a Ventana Discovery XT staining platform using
the Ventana DAB Map Kit. An in-house monospeciﬁc polyclonal
rabbit antiserum was used to detect human SAP and a mouse
monoclonal antibody was used to detect NPTX1 (Supplementary
Table 2). Sections were counterstained with hematoxylin.
Blood–Brain Barrier Breakdown and Entry of SAP
into the Brain
In order to test the ability of SAP to cross a compromised blood–
brain barrier, a protocol modiﬁed from Veszelka et al. (2013) and
Bien-Ly et al. (2015) was used. Brieﬂy, 4- to 6-month-old male
Table 1 Postmortem sporadic Alzheimer’s disease cases
Case
number
Age at
onset
Age at
death
Duration
(years)
Gender
1 80 85 5 M
2 46 52 6 F
3 58 68 10 M
4 54 64 9 M
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C57BL/6 mice were given 2 intraperitoneal injections of lipopoly-
saccharide (LPS, from Escherichia coli 0111:B4; Sigma-Aldrich;
100 μg per injection per mouse dissolved in phosphate-buffered
saline) or vehicle at 0 and 6h. Mice then received a further injec-
tion of either 250 μg puriﬁed native human SAP (Abcam) in
20mM phosphate buffer or vehicle at 22 h. Mice were perfused
with phosphate-buffered saline at 24h and the brain dissected
and snap frozen for Western blot analysis.
Statistics
In order to assess the impact of treatment on paired-pulse
ratios, repeated measures ANOVAs were conducted. As experi-
ments were designed such that control experiments were
interleaved between the different pentraxin treatments, the
control group is common to all experiments. Therefore, to
examine the effects of chronic pentraxin treatment, statistical
analysis was performed as a one-way ANOVA comparing all
treatments. We included the 25ms interval only, with experi-
ments at longer interpulse intervals performed to ensure the
expected depreciating interaction between the 2 excitatory
postsynaptic currents (EPSCs) as the paired-pulse interval
increases. To examine the effects of acute treatment, a two-
way ANOVA was performed, with treatment and time as main
effects (time as a repeated measure), as well as a treatment by
time interaction term. Where appropriate, post hoc compari-
sons were conducted, adjusted with the Šidák correction for
multiple comparisons. All statistical analyses were performed
using Prism6 (GraphPad Software).
All sample sizes are expressed as number of animals. When
multiple cells or slices were recorded from one animal, a mean
value for that animal was obtained prior to an overall mean ±
standard error of the mean (SEM) from all animals. In the case
of patch-clamp recordings from organotypic slices, each slice is
considered as independent, despite originating from the same
pup and, therefore, sample sizes represent the number of slices
from which cells were recorded. However, data for each group
were obtained from a maximum of 3 slices prepared from any
single animal. In all cases, only one cell was obtained from a
single slice.
Results
Acute Application of NPTX1 Increases Paired-Pulse
Ratios at Schaffer-Collateral Synapses
Initially, to investigate whether we could detect acute effects of
NPTX1 on synaptic transmission in the hippocampus, patch-
clamp recordings of EPSCs from CA1 pyramidal neurons were
conducted in organotypic hippocampal slices. EPSCs were
recorded in response to pairs of electrical stimuli applied
every 10 s to Schaffer collaterals in the presence of the GABAA
(γ-aminobutyric acid) receptor antagonist, gabazine (6 μM).
Paired-pulse ratios (the amplitude of the second divided by
amplitude of the ﬁrst of a pair of response) were determined
in order to test for alterations in probability of glutamate release,
with the probability of release of transmitter in response to the
ﬁrst stimulus inversely proportional to paired-pulse ratio (Zucker
1989; Dobrunz and Stevens 1997). As expected at this synapse,
paired-pulse facilitation was observed across all control experi-
ments (Fig. 1). The interpulse interval between each pair of stim-
uli was set at 25ms. After a 5-min period of stable baseline
recording, NPTX1 (60 nM) was added to the perfusion medium
and stimulation continued. There was no change in paired-pulse
ratio over time when no pentraxin was included in the bath
solution. In contrast, when NPTX1 was washed onto the slice,
the paired-pulse ratio increased (Fig. 1A), suggesting that acute
application of NPTX1 decreases the release probability of gluta-
mate. As control experiments were interleaved with those for
NPTX1 and SAP (see below), control data are common to both. A
signiﬁcant interaction of treatment and time (P < 0.05) was
observed and Šidák post hoc multiple comparisons showed sig-
niﬁcance at both the 5- and 10-min time points.
Chronic Application of Neuronal Pentraxins Decreases
Paired-Pulse Ratio and Down Regulates Response
to Acute Application
Considering the direct effect of NPTX1 on glutamate release
when applied acutely and the evidence that expression of
NPTX1 is increased in the presence of amyloidβ, we went on
to examine the effect of constant exposure of organotypic
slices to low levels of NPTX1 over 7 days. In contrast to acute
application, chronic application of NPTX1 resulted in a dose-
dependent decrease in paired-pulse ratios, with signiﬁcant
effects at 60 and 100 nM (Fig. 1B; summarized in Fig. 1F). Note
that, in these chronic experiments, NPTX1 was applied to the
culture medium of the organotypic slices over 7 days but
little, if any, would be present in the perfusion solution during
recording after a minimum of 30min washing. Hence, once
the NPTX1 is washed out after chronic exposure, the prob-
ability of glutamate release in control solution goes in the
opposite direction from the effect of acute exposure. This
presumably reﬂects a homeostatic response, maintaining the
network balance during the long-term presence of this syn-
aptic modulator.
In a subsequent series of experiments, to test the effect of
acute application after chronic exposure, we applied acute
NPTX1 (60 nM) to slices that had been chronically treated as
above. Under these conditions, the effect of acute application
was completely lost (Fig. 1A) demonstrating a down-regulation
of the response to acute NPTX1 after chronic exposure. Hence,
assuming that there is physiologically some ongoing release of
NPTX1, the paired-pulse ratio in control solution would be
slightly increased compared with the paired-pulse ratio in the
complete absence of NPTX1 (or similarly acting neuromodula-
tors). However, after chronic exposure, the loss of the effect of
acute NPTX1 would prevent the endogenous modulation. This
would be compatible with the decrease in paired-pulse ratio
(increased release probability) resulting from chronic exposure.
Chronic application of NPTX2 or NPTXR (Fig. 1C,D, respect-
ively; summarized in Fig. 1F) was found to have similar effects
to NPTX1, with NPTXR having a potency in the same range as
NPTX1. NPTX2 was rather less potent, with no measureable
effects at 70 nM but increasing release probability at the highest
concentration of 420 nM.
As the chronic experiment was designed such that control
experiments were interleaved between the different pentrax-
in treatments, the control group is common to all experi-
ments. Therefore, statistical analysis was performed as a
single one-way ANOVA, considering the 25ms interval only
(P < 0.0001). The 25ms interval paired-pulse ratios are sum-
marized in Figure 1F, where Šidák post hoc multiple compari-
sons are shown, comparing each pentraxin treatment to
control. Note that the acute application of NPTX1, after
chronic exposure, was a subsequent series of experiments
and hence had controls interleaved with treated slices inde-
pendently of the above.
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Exposure of Hippocampal Synapses to the Peripheral
Pentraxin SAP has Similar Effects to Neuronal
Pentraxins
As expected, we detected no signiﬁcant expression of SAP at the
RNA level in the hippocampus, cortex or cerebellum of 4 months
old wild type mice using PCR (Supplementary Fig. 1A). Similarly,
no expression of SAP was detected using microarray analysis of
these brain regions of wild type mice or mice transgenic for
genes for familial Alzheimer’s disease at 2, 4, 8, and 18 months
of age (www.mouseac.org; see Matarin et al. 2015). This is as
expected, as SAP is an acute-phase protein in mice (Baltz et al.
1980; Bottomley et al. 1988) most likely expressed exclusively in
the liver (Yasojima et al. 2000; Mulder et al. 2010; Hawrylycz et al.
2012; www.brain-map.org). However, SAP has been reported to
be detectable in the cerebrospinal ﬂuid (Hawkins 1994) and on
plaques (Kalaria et al. 1991) of Alzheimer’s disease patients and
so, to reach the concentrations reported in CSF, must penetrate
the blood–brain barrier, possibly due to blood–brain barrier
breakdown. We thus investigated whether SAP has direct effects
upon synaptic transmission in the central nervous system.
Native puriﬁed human SAP (20 nM) applied acutely to organoty-
pic slices also had a similar effect to the acute application of
NPTX1, resulting in an increase in paired-pulse ratio (Fig. 1A),
suggesting that SAP can also have direct effects by decreasing
glutamate release probability.
SAP was also added chronically to the culture medium of
hippocampal organotypic slices exactly as for the NPTXs above.
Hence, the effect of applications of SAP (0, 5, and 20 nM) were
compared with the effects of similar concentrations of NPTX1
after 7-day exposure and, like NPTX1, paired-pulse ratios were
decreased in a dose-dependent manner, again suggesting an
increase in release probability (Fig. 1E; summarized in Fig. 1F).
Together these results suggest that SAP and NPTX1 have simi-
lar, potent presynaptic effects at CA3-CA1 synapses.
Effects of Transgenic Expression of Human SAP
in Mice In Vivo
As SAP is expressed in the liver, we tested whether the effects
seen above would occur if human SAP was expressed on the
human SAP promoter in the liver of transgenic mice (Iwanaga
et al. 1989). These mice have a steady state SAP plasma concen-
trations within the human range (ibid). Acute hippocampal
brain slices were prepared from 14-month-old animals and
patch-clamp experiments were performed. Interestingly, these
mice showed an even greater decrease in paired-pulse ratio
than seen with the 7-day application of SAP, with almost no
facilitation seen throughout the interpulse intervals used and
thus signiﬁcant differences between the SAP and WT mice at
all interpulse intervals between 25 and 100ms (Fig. 2A). A stat-
istically signiﬁcant genotype by interval interaction (P < 0.01)
was also observed, reﬂecting the lack of the usual effect of
increasing the interval between pulses in the transgenic mice.
In acute slices, it is possible to use minimal stimulation in
which only one or a few axons is stimulated, thus allowing the
analysis of failures to release transmitter. In order to verify that
the changes in paired-pulse ratio represented a change in
Figure 1. Pentraxins modulate probability of glutamate release at CA3-CA1
synapses. Voltage-clamp recordings from CA1 pyramidal neurons in response
to pairs of stimuli to Schaffer collaterals in hippocampal organotypic slices. (A)
Acute application of NPTX1 (n = 9 slices) or SAP (n = 8) increased paired-pulse
ratio at 25ms interpulse interval. In each slice, 15 traces were averaged across
5min preceding the indicated time point. *P < 0.05; **P < 0.01. Šidák post hoc
multiple comparisons compared with time-matched control (n = 6). In a differ-
ent series of experiments, effects of acute application of 60 nM NPTX1 on
paired-pulse ratio are shown in slices pretreated for 7 days with 60 nM NPTX1
(n = 8). Traces show typical paired-pulse ratio responses at 25ms interpulse
intervals from control and pentraxin-treated slices. Black traces: baseline
(0min); gray traces: 5min treatment. Scale bar: 10 pA x 10ms. (B) Treatment
with recombinant human NPTX1 for 7 days resulted in a dose-dependent
decrease in paired-pulse ratio. Control n = 26; 6 nM, n = 6; 60 nM, n = 7; 100nM,
n = 4 slices. Traces show typical paired-pulse ratio responses at 25ms interpulse
intervals from control (black) and NPTX-treated (gray) slices. Scale bar: 10 pA x
5ms. (C) Treatment with recombinant human NPTX2 for 7 days gave rise to a
dose-dependent decrease in paired-pulse ratio. Control n = 26; 70 nM, n = 4;
420 nM, n = 7 slices. (D) Treatment for 7 days with recombinant human NPTX
receptor (n = 5) also decreased paired-pulse ratio compared with control (n = 26).
(E) Treatment with human SAP for 7 days reduced paired-pulse ratios in a dose-
dependent manner. Control n = 26 (same control preparations in B, C, and D);
5 nM, n = 5; 20 nM, n = 9 slices. Traces show typical responses from paired-pulse
stimuli at 25ms interval from control (black) and SAP-treated (gray) slices. Scale
bar: 10 pA x 10ms. (F) Summary data of the chronic application of pentraxins,
showing only paired-pulse ratios from 25ms interpulse intervals. One-way
ANOVA was highly signiﬁcant (P < 0.0001). Šidák post hoc multiple comparisons
are shown compared with control, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Panels A–F are presented as mean ± SEM across slices.
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release probability in the SAP transgenic mice the effect of min-
imal stimulation was tested to isolate one or very few CA3
axons. The mean failure rate was lower in SAP mice than in
wild type littermates (Fig. 2B), conﬁrming an increase in gluta-
mate release probability, consistent with the decreased paired-
pulse ratios.
In the same cohort of animals, we recorded ﬁeld potentials
from CA1 stratum radiatum in response to stimuli applied to
Schaffer collaterals in acute brain slices. Responses tended to
be larger in transgenic SAP mice (Fig. 2C) and, similarly to the
voltage-clamp recordings above, paired-pulse ratios were lower
(Fig. 2D). The magnitude of long-term potentiation induced by a
tetanic stimulus was signiﬁcantly smaller in slices from SAP
mice compared with wild type mice (Fig. 2E). So again, it is clear
that central transmission and, furthermore, synaptic plasticity
can be inﬂuenced in mice with SAP levels tonically raised life-
long, due to expression of human SAP from the liver.
When considered together, the data from exogenous applica-
tion of SAP to organotypic brain slices and experiments per-
formed in acute brain slices from transgenic animals expressing
human SAP, clearly demonstrate that chronic exposure to SAP
positively modulates glutamate release and that sufﬁcient SAP
can enter the brain of the mouse to cause this effect, even
when only expressed in the liver. Moreover, with long-term
exposure, the magnitude of long-term potentiation was also
reduced.
NPTX1 and SAP Interact When Applied to Organotypic
Slices or When Overexpressed in Human Embryonic
Kidney Cells
NPTX1 (6 nM; submaximal concentration) was included in the
culture medium of organotypic slices for 7 days (as above)
together with SAP (5 or 20 nM) and the effects compared with
interleaved experiments comparing NPTX1 or SAP alone at the
same concentrations. As the interleaved experiments were not
different from the previous experiments using these concentra-
tions, the data were pooled (Fig. 3A,B). SAP affected paired-
pulse ratio alone at both concentrations as did 6 nM NPTX1 but
combining NPTX1 and SAP did not result in an additional effect
to that of application of NPTX1 alone. As described above, pen-
traxin treatments and experiments, where no pentraxin was
applied, were interleaved and thus controls are common to all
experiments and thus statistical analysis performed as a single
one-way ANOVA (P < 0.0001). The absence of an additive effect
of coapplication suggests that the 2 pentraxins are not acting
independently but interact with the same target when applied
together. Moreover, this implies that, when SAP enters the
brain, it could interact with the endogenously released NPTX1,
either at the level of NPTX1 or at downstream targets.
To investigate the possible interactions of central and periph-
eral pentraxins further, HEK cells were cotransfected with pairs
of NPTXs, or with SAP and a NPTX. The possibility of complex
Figure 2. Transgenic expression of human SAP reduces paired-pulse ratio and long-term potentiation at CA3-CA1 synapses. Acute hippocampal brain slices were pre-
pared from TgSAP mice expressing human SAP on its own promoter and ﬁeld potentials recorded from stratum radiatum in response to Schaffer-collateral stimula-
tion. (A) Paired-pulse ratios measured with voltage-clamp were lower in slices from transgenic animals (n = 9 animals) compared with controls (n = 8). Repeated
measures ANOVA revealed an interaction between genotype and interval (P < 0.02). Šidák post hoc comparison to control at the same interpulse interval are indicated
*P < 0.05; ****P < 0.0001. The example EPSCs (top right panel) are from the 25ms interpulse interval. Scale bar: 5 pA x 10ms. (B) Failure rate for evoked EPSCs at minimal
stimulation (WT, n = 7; TgSAP, n = 5 animals; **P < 0.01, unpaired t-test). (C) Input–output relationships for fEPSPs at CA3-CA1 synapses in slices from WT (n = 9 ani-
mals) and TgSAP (n = 8 animals). (D) Paired-pulse ratios determined from fEPSPs evoked in slices from WT and TgSAP mice. (E) Long-term potentiation was induced
by tetanic stimulation at time zero (vertical dashed line). Two-tailed unpaired t-test comparing the means of the last 10min is indicated by *P < 0.05. Example fEPSPs
are shown above from the approximate times indicated by 1 and 2. Scale bar: 0.2mV × 5ms. Panels A–E are presented as mean ± SEM.
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formation was subsequently tested by coimmunoprecipitation.
Considering the similarity in structure of the NPTXs and SAP, we
tested the speciﬁcity of the antibodies by overexpressing each
individual pentraxin in HEK cells and subsequent Western
immunoblot and identiﬁed a speciﬁc antibody for each pentraxin
(Supplementary Fig. 2A,B). The relative afﬁnity of each of these
speciﬁc pentraxin antibodies to its respective target was deter-
mined using serial dilutions of puriﬁed/recombinant pentraxin
proteins, with concentrations of all the puriﬁed/recombinant
pentraxins independently veriﬁed (Supplementary Fig. 2C,D).
The SAP antibody showed higher afﬁnity than the NPTX1 anti-
body (Supplementary Fig. 2D). As reported previously, NPTX1,
NPTX2, and NPTXR can form heteropentamers (Kirkpatrick
et al. 2000; Xu et al. 2003) as reﬂected here in their coimmu-
noprecipitation when expressed together in HEK cells
(Fig. 3C). Interestingly, SAP was also found to form a complex
with NPTX1, NPTX2, or NPTXR (Fig. 3C), thus further suggest-
ing that the effects of SAP on synaptic transmission could be
due to interactions with the NPTXs.
SAP and NPTX1 Accumulate Around Plaques
in Hippocampus and Cortex of Alzheimer’s Patients
Considering, in different reports, both NPTX1 and SAP have
been reported to be associated with neuritic plaques in post-
mortem brain tissue of people with Alzheimer’s disease, we
went on to compare the localization of these pentraxins in
postmortem brains from Alzheimer’s patients using the anti-
bodies, the speciﬁcity of which we had established above
(Supplementary Fig. 2A,B). NPTX1 showed very strong staining
of dystrophic neurites around the periphery of plaques as well
as a general diffuse staining between the neurons but little, if
any, staining in the core of the plaque. In addition, there was a
general punctate staining of nerve terminals throughout the
tissue. This staining of nerve terminals reﬂects the normal dis-
tribution of NPTX1 as seen in human (Fig. 4A) or wild type
mouse brains (Fig. 4B). In the Alzheimer’s disease human post-
mortem brain, NPTX1 staining was also seen in dystrophic neu-
rons remote from plaques, which may represent neurons with
tau pathology (Fig. 4Aii).
SAP staining was also seen in association with plaques in
postmortem brains from Alzheimer’s disease patients (Fig. 4C).
Although very faint, this staining was present diffusely around
the plaques but was not evident elsewhere in the tissue. As the
SAP antibody showed higher afﬁnity than the NPTX1 antibody
for their respective targets (Supplementary Fig. 2D), the relative
strength of antibody staining suggests that only relatively little
SAP is present on the plaque compared with NPTX1. This is
perhaps not surprising as the NPTX1 is produced in glutamater-
gic nerve terminals and so this staining likely represents locally
released NPTX1, possibly from the dystrophic neurites them-
selves. Hence, unless structural changes of the proteins when
bound around amyloid plaques results in a differential change
in the binding of the antibodies, the pentraxin binding to pla-
ques is strongly dominated by the NPTX, NPTX1, when com-
pared with SAP. Little, if any, speciﬁc staining was detected in
the hippocampus of SAP transgenic mice, although some stain-
ing was evident in the ﬁmbria (Fig. 4D).
SAP Can Enter the Brain When the Blood–Brain Barrier
is Compromised
Under normal conditions, SAP would not be expected to cross
the blood–brain barrier and yet we know that it can enter the
brain in Alzheimer’s disease as evidenced by its presence on
plaques. We hypothesize that it could cross under conditions of
blood–brain barrier breakdown as has been reported to occur in
AD or under conditions of inﬂammation or other disease condi-
tions. While soluble SAP would be expected to be broken down
or be otherwise removed from the brain (Veszelka et al. 2013),
its binding to plaques could prevent its removal. We thus tested
for levels of mouse and/or human SAP in the brain using
Western blot in wild type mice after injection of human SAP
with or without compromising the blood–brain barrier by treat-
ment with LPS (Fig. 5; Veszelka et al. 2013; Chisholm et al. 2015).
In the absence of LPS, we could detect only very low levels of
SAP in the brain of untreated mice or mice injected with human
SAP (250 µg). However, 22 h after the ﬁrst of 2 LPS administra-
tions, injection of human SAP resulted in a strong signal in both
hippocampus and cerebellum. Furthermore, even without injec-
tion of human SAP, endogenous mouse SAP levels were
increased in the brain, albeit at rather variable levels (Fig. 5).
Two-way ANOVA conﬁrmed a signiﬁcant effect of LPS (P = 0.01)
and no signiﬁcant effect of SAP injection and no interaction.
Figure 3. SAP forms complexes with each of the NPTXs and affects synaptic
transmission. (A,B) Effect of coapplication of NPTX1 and SAP on paired-pulse
ratios at CA3-CA1 synapses. (A) Comparison of 6 nM NPTX1 and 5 nM SAP
applied individually or together. Control, n = 26; 6 nM NPTX1, n = 6; 5 nM SAP,
n = 5; NPTX1 and SAP, n = 6 slices. (B) Comparison of 6 nM NPTX1 and 20 nM
SAP applied individually or together. Control, n = 26; 6 nM NPTX1, n = 6; 20 nM
SAP, n = 9; NPTX1 and SAP, n = 6 slices. Šidák post hoc comparisons are shown
for coapplication versus control at 25ms intervals *P < 0.05. Panels A and B are
presented as mean ± SEM. (C) HEK293T cells were transfected with constructs
expressing the combinations of pentraxins indicated, each fused to GFP. After
48 h, lysates were collected and tested by IP followed by Western blotting (WB)
with antibodies speciﬁc to each pentraxin. The bands correspond to the
molecular weight predicted for each full-length pentraxin fused to GFP, with
molecular weights for GFP ~27 kDa, SAP ~25 kDa, NPTX1/2 ~47 kDa, and NPTXR
~53 kDa (Supplementary Fig. 2A,B). Note: the NPTX1 and NPTXR antibodies
were not effective at IP, even for NPTX1 and NPXTR themselves, in part due to
lower afﬁnity (see Supplementary Fig. 2D).
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Discussion
Novel Effects of Pentraxins on Synaptic Transmission
NPTX1 and NPTX2 have previously been shown to affect
postsynaptic elements of glutamatergic synapses in the
hippocampus causing clustering of AMPA receptors (Xu et al.
2003). We conﬁrm here the distribution of NPTX1 in hippo-
campal glutamatergic nerve terminals, as reported by Cho
et al. (2008). Moreover, we demonstrate here for the ﬁrst time
that all 3 NPTXs and also the peripheral pentraxin SAP have
effects presynaptically, strongly decreasing paired-pulse
ratio when added to the culture medium of organotypic
slices over a 7-day period. This also occurs in transgenic
mice overexpressing human SAP. Moreover, in the latter
case, experiments using minimal stimulation conﬁrmed that
failure rates decreased and thus that the change in paired-
pulse ratio was due to an increase in glutamate release
probability.
Interestingly, when NPTX1 or SAP was added acutely, the
opposite effect was seen with an increase of paired-pulse ratio,
suggesting that the direct effect of the pentraxins is a decrease
in probability of evoked glutamate release. The observation
that acute effect of NPTX1 is lost, after chronic exposure, sug-
gests that the effect of chronic application is a homeostatic
reaction, decreasing the sensitivity to acute pentraxins. Hence,
when the background pentraxin level is chronically raised by
adding NPTX1 to the culture medium, rather than the release
of glutamate remaining low, physiologically released pentrax-
ins lose their efﬁcacy so that compared with untreated synap-
ses the average release probability is increased. It is possible
Figure 4. Comparison of the distribution of NPTX1 and SAP in glutamatergic terminals and on amyloid plaques. (A) Postmortem Alzheimer’s hippocampus stained for
NPTX1 (brown diaminobenzidine staining). (Ai) NPTX1 is evident in the hippocampus, particularly within the polymorphic layer of the dentate gyrus, stratum luci-
dum of CA3 and stratum radiatum of CA1. 4× objective. (Aii) A neuroﬁbrillary tangle (white arrowhead) distal to neuritic plaques (black arrowheads) in the hippocam-
pus. Both are heavily stained for NPTX1. 20× objective. (Aiii) A higher magniﬁcation (40× objective) image showing NPTX1 associated with a neuritic plaque in the
temporal cortex. (B) NPTX1 staining in the hippocampus of an adult wild type mouse. Note the similar pattern of staining to human (i.e., polymorphic layer of dentate
gyrus, particularly heavy staining in stratum lucidum of CA3 and lighter staining in stratum radiatum of CA1; but in the case of the mouse, also in all layers of CA3
and in stratum oriens in CA1). (Bii) Higher magniﬁcation image of the CA1. The area of interest is indicated in (Bi). Note the presence of NPTX1, particularly in stratum
radiatum (SR) and stratum oriens (SO) but a near-absence in stratum pyramidale (SP) and stratum lacunosum moleculare (SLM). (C) Postmortem AD hippocampus
stained for SAP. (Ci) Note the lower level of staining compared with NPTX1. 4× objective. (Cii) Cortical plaques stained for SAP. (Ciii) Higher magniﬁcation image (40×
objective) of plaques stained for SAP. (D) Transgenic SAP mouse hippocampus stained for SAP. (Di) Little (if any) speciﬁc staining. (Dii) Higher magniﬁcation image of
CA1. Area of interest indicated by box on Di. Panels A–D: brown staining is NPTX1 or SAP.
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that the clustering of AMPA receptors, previously reported, is a
homeostatic response to overexpression of the NPTXs, as this
would also increase the efﬁcacy of glutamate transmission (Xu
et al. 2003). Moreover, it has been suggested that pentraxins
could have an intracellular mode of action, as evidenced by the
apoptosis-induced upregulation of NPTX1, which targets mito-
chondria, leading to their fragmentation (Clayton et al. 2012).
Indeed, mitochondrial regulation of calcium within the pre-
synaptic terminal can modulate glutamate release (Scotti et al.
1999).
The question arises as to how the acute and chronic applica-
tion of the pentraxins in organotypic slices relate to the effects
of pentraxins in vivo. Figueiro-Silva et al. (2015) examined the
effects of NPTX1 in vivo using lentivirus knockdown of NPTX1.
Interestingly, they observed enhanced long-term potentiation
but no change in paired-pulse ratio of ﬁeld EPSPs recorded in
behaving mice. Unless prevented by compensation (e.g., by
upregulation of other NPTXs), the knockdown of NPTX1 would
be expected to have the same effect as chronically applied
NPTX1 used in the present study in which the effect is lost due
to desensitization rather than lack of the protein. Considering
the similarity in the effects of the different pentraxins observed
in the present study, the lack of effect on paired-pulse ratio
after knockdown, likely suggests that other pentraxins are up-
regulated to compensate or that the sensitivity to the remain-
ing NPTX1 is increased under these conditions. In contrast,
after high-frequency stimulation, the differences in synaptic
plasticity were seen in the above study, with the enhance-
ment of responses evident over several days. In acute hippo-
campal slices from the SAP transgenic mouse (that mimic the
effects of chronic exposure to NPTXs), long-term potentiation
was impaired. This is consistent with the enhancement
reported by Figuero-Silva et al. in the mouse after knockdown
of NPTX1.
How Does This Relate to Alzheimer’s Disease?
Both SAP and NPTX1 have been reported previously and are con-
ﬁrmed here, to be present on amyloid plaques in Alzheimer’s
disease. In the present study by comparing the 2 pentraxins
under similar conditions, we can compare the relative amounts
of SAP to NPTX1 on plaques. The question arises as to whether
they play an active role in the disease in this or other contexts.
The present study suggests that, while they are both present on
plaques, NPTX1 dominates and so the effect of SAP would be, at
most, subtle. Although it is not impossible that low levels of SAP
may inﬂuence the deposition of amyloidβ, what is clear that its
presence on plaques in postmortem brains is indicative of its
ability to enter the brain. This suggests that the effects observed
here of soluble SAP on synaptic transmission, at very low con-
centrations, could be important physiologically, resulting in pro-
found effects on neuronal function, particularly when increased
by blood–brain barrier breakdown, as reported in Alzheimer’s
disease (Blennow et al. 1990; Montagne et al. 2015). We suggest
that the synaptic effects of SAP probably involve the same path-
ways as the effects of NPTXs and are possibly due to direct
molecular interaction between the pentraxins.
A further observation of interest in these experiments in
human brain was that all the dystrophic neurites within the
plaque showed strong NPTX1 staining. As there is no evidence
of NPTX1 being taken up by dendrites, this would suggest that
the neurites seen in plaques are axonal boutons, rather than
dendrites.
Recently, we have reported in mice transgenic for genes that
cause familial Alzheimer’s disease (hemizygous TASTPM;
APPSwe/PSEN1M146V) that the ﬁrst effect of rising amyloidβ is an
increase in glutamate release probability (Cummings et al.
2015), very similar to that reported here after chronic exposure
to NPTXs. This is consistent with the effect of amyloidβ in nor-
mal rats when released in response to speciﬁc stimulus para-
digms (Abramov et al. 2009) and would be compatible with
reports that some of the effects of amyloidβ may be mediated
by increasing NPTX1 expression (Abad et al. 2006).
Is Inﬁltration of SAP into the Brain Likely to Affect
Synaptic Transmission Under Other Conditions?
The present study clearly shows that SAP can have effects on
synaptic transmission when applied to organotypic slices at
low nanomolar concentrations. Moreover, the concentration
gradient between plasma and brain is reported to be in the
region of 1000-fold (Nelson et al. 1991; Kolstoe et al. 2009) and
thus, in cases of blood–brain barrier breakdown, SAP concentra-
tions could increase markedly, directly affecting synaptic trans-
mission or, perhaps more likely, interacting with released
NPTXs. The observation that SAP can enter the brain under
conditions of blood–brain barrier breakdown is thus compatible
with the reported 1000-fold concentration gradient between
plasma and brain (Nelson et al. 1991; Kolstoe et al. 2009).
Inﬁltration of SAP into the brain under conditions of blood–
brain barrier breakdown would be relevant not only to
Alzheimer’s and other diseases in which prolonged blood–brain
barrier breakdown occurs (Blennow et al. 1990), but also to con-
ditions such as stroke and other vascular incidents or during
various types of inﬂammation. Under such conditions, spikes
of SAP inﬁltrating the brain could have major short-term effects
on cognition. It is interesting that similar effects are seen in
mice with human SAP expressed in the liver, suggesting that
sufﬁcient SAP can enter the brain to have effects, even under
Figure 5. SAP crosses the compromised blood–brain barrier. Mice were adminis-
tered LPS to compromise the blood–brain barrier, injected with native human
SAP and hippocampus probed for SAP. (A) Western blot showing SAP levels in
the 4 groups of mice. Liver from an animal injected with SAP is shown in the
last lane as a positive control. (B) SAP levels were normalized to total protein
levels (Ponceau-S). Data presented as mean ± SEM from 2 animals per group.
Main effect of LPS, P = 0.01 (two-way ANOVA).
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physiological conditions. Interestingly, the synaptic effects of
SAP in the transgenic mice also resulted in a decrease in long-
term potentiation in response to tetanic stimulation. It seems
likely that the greatly increased release probability observed in
the transgenic mice is directly related to the loss of long-term
potentiation. This could result in a rapid depletion of readily
available vesicles during high-frequency stimulation leading to
failure of synaptic transmission during the conditioning train,
hence decreasing the time course of Ca2+ inﬂux on which the
plasticity depends.
The question arises as to how the SAP gets into the brain of
the transgenic mice. It is possible that SAP is having an effect
peripherally that results in changes in factors that can cross
the blood–brain barrier, rather than SAP itself entering the
brain. However, the similarity between the effects of exogen-
ously applied SAP and the insertion of a transgene for SAP into
mice suggests that the effects seen are directly due to the pres-
ence of SAP in the brains of the transgenic animals. We ﬁnd
that exogenously applied SAP has effects at concentrations as
low as 20 nM, if the organotypic slice is exposed for 7 days. The
transgenic mice are exposed to SAP throughout life and so it is
possible that even lower levels can modulate synaptic trans-
mission under these conditions. On the other hand, it is also
possible that the blood–brain barrier is compromised from time
to time during the life of the mouse and that this results in
slightly higher levels in the brain. Finally, although we and
others (Mulder et al. 2010; Hawrylycz et al. 2012 [www.brain-
map.org]; Matarin et al. 2015 [www.mouseac.org]) ﬁnd little or
no evidence for expression of SAP within the brain, there still
remains the possibility of local synthesis (Yasojima et al. 2000)
which may be below detection thresholds in most studies.
Whatever the ﬁnal concentrations within the synapse, it is
clear that very low levels of SAP in the brain can result in
changes to synaptic transmission.
How is SAP Affecting Synaptic Transmission?
The most likely explanation for the effects of SAP on central syn-
aptic transmission is that it is mimicking the structurally related
NPTXs, which are highly expressed in the brain. The fact that its
effect when coapplied with NPTX1 is not additive suggests that,
at some level, they are interacting or affecting the same targets.
The observation that SAP and the NPTXs can be pulled down
together in coimmunoprecipitation experiments suggests that
SAP may be able to contribute to heteromultimeric complexes of
NPTXs, altering their activity. However, it is also possible that
they are pulled down together because they can simultaneously
bind to other common partners.
Moreover, although SAP and NPTX1 are both present around
amyloid plaques in postmortem brains of people with
Alzheimer’s disease, only NPTX1 appears elsewhere in the
hippocampus and cortex. Hence, while NPTX1 is clearly present
in presynaptic terminals in both mouse and man, we see no
evidence of the presence of intracellular SAP in hippocampus
or cortex even when expressed transgenically on a WT mouse
background. Thus, the effect of SAP on synaptic transmission
in the transgenic mice is presumably due to the presence of
soluble SAP in the extracellular space, which is washed out
when the brain is perfused during tissue preparation, rather
than due to formation of pentamers within the neurons. It is
thus more likely that the interaction relates to competition
between these closely related molecules rather than direct
interaction between the peripheral and central pentraxins,
although this can also occur.
In conclusion, the NPTXs have strong presynaptic effects on
glutamatergic transmission in the CNS at low nanomolar concen-
trations and particularly NPTX1 is widely distributed throughout
the synaptic terminals of the hippocampus and cortex. It is inter-
esting to note that all the pentraxins tested have similar effects
on synaptic transmission, although NPTX2 shows a rather lower
potency. Considering previous reports of postsynaptic effects of
NPTX2 and other NPTXs (O’Brien et al. 1999; Xu et al. 2003; Chang
et al. 2010), this may suggest that the primary effects of different
NPTXs may differ, resulting in complementary, if overlapping,
effects on synaptic transmission.
We conﬁrm previous reports that sufﬁcient concentrations
of the peripheral pentraxin, SAP, enter the brain in Alzheimer’s
disease for it to be detectable on plaques, albeit modestly com-
pared with NPTX1. Independent of interactions with plaques,
the interaction of SAP with the NPTXs may also cause disrup-
tion to the normal synaptic effects of NPTXs in the brain.
Certainly at the concentrations studied here, SAP mimics the
effects of NPTX1 and also the effects of amyloidβ, as seen in the
earliest stages of transgenic mice carrying familial Alzheimer’s
disease mutations (Cummings et al. 2015). Overall, the evidence
presented here strongly suggests that SAP can enter the brain
under some conditions and so would have the opportunity to
interact with the NPTXs, inﬂuencing central synaptic transmis-
sion in Alzheimer’s disease but also under other conditions of
blood–brain barrier breakdown.
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